Firms ally to develop drug for cancer, autoimmune disease

05/17/2013 | Genetic Engineering & Biotechnology News

RuiYi and Genor Biopharma agreed to co-develop the former's experimental monoclonal antibody drug RYI-008 against cancer and autoimmune diseases, particularly rheumatoid arthritis, in China. The deal follows RuiYi's announcement that it would use CMC Biologics' CHEF1 high-productivity expression plasmid to speed work on a cell line for RYI-008.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC